Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06633757 · ClinicalTrials.gov registry record · Phase 1
Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
A Phase 1 study of Primary Ciliary Dyskinesia (PCD), sponsored by ReCode Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT06633757: Active Phase 1 study of Primary Ciliary Dyskinesia (PCD), sponsored by ReCode Therapeutics.
NCT06633757 is a Phase 1 study of Primary Ciliary Dyskinesia (PCD) that is active but no longer recruiting, run by ReCode Therapeutics. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06633757, a Phase 1 study of Primary Ciliary Dyskinesia (PCD), is active but no longer recruiting, sponsored by ReCode Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
Primary Outcome
The Change in Mucociliary and Cough Clearance through 1 hour after radiotracer administration by either the albumin-based PRMC or sulfur-colloid technique
Conditions Studied
Interventions
- DRUG RCT1100
Study Locations (3)
North Carolina
- UNC - Chapel Hill
Other
- Copenhagen University Hospital - Rigshospitalet - Copenhagen
North Rhine-Westphalia
- Münster University Hospital, Albert-Schweitzer-Campus 1 - Münster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 1 |
What the registry record for NCT06633757 still lists
NCT06633757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Primary Ciliary Dyskinesia (PCD) appearing as the primary indexed condition, and to 1 intervention - of which RCT1100 is the first listed.
NCT06633757 reports a single indexed study location in North Carolina, Other, North Rhine-Westphalia.
Frequently Asked Questions
What is clinical trial NCT06633757 about?
NCT06633757 is a clinical study titled "Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance". This is a multi-dose study with RCT1100 and is designed to provide safety, tolerability and preliminary efficacy data for future clinical studies.
What is the current status of trial NCT06633757?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-10-22. Estimated completion is 2025-12-30.
What conditions does trial NCT06633757 study?
This clinical trial studies the following conditions: Primary Ciliary Dyskinesia (PCD).
What interventions are being tested in trial NCT06633757?
The interventions under investigation include: RCT1100 (DRUG).
Who is sponsoring clinical trial NCT06633757?
This trial is sponsored by ReCode Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06633757 being conducted?
This trial has 3 study locations across North Carolina, North Rhine-Westphalia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06633757's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI